ArticleOncotarget2018
Aberrant frequency of TNFR2
Article in Oncotarget, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.
- Elevation of circulating TNF receptor 2 in cancer: A systematic meta-analysis for its potential as a diagnostic cancer biomarker.Frontiers in immunology · 2022Pooled it
- Review
- Different subpopulations of regulatory T cells in human autoimmune disease, transplantation, and tumor immunity.MedComm · 2022Review
- The effects of TNF-α/TNFR2 in regulatory T cells on the microenvironment and progression of gastric cancer.International journal of cancer · 2022Article
- Role of FoxP3-positive regulatory T-cells in regressive and progressive cervical dysplasia.Journal of cancer research and clinical oncology · 2022Article
- Antagonistic Antibody Targeting TNFR2 Inhibits Regulatory T Cell Function to Promote Anti-Tumor Activity.Frontiers in immunology · 2022Article
- The augment of regulatory T cells undermines the efficacy of anti-PD-L1 treatment in cervical cancer.BMC immunology · 2021Article
- Review
- The TNF-α/TNFR2 Pathway: Targeting a Brake to Release the Anti-tumor Immune Response.Frontiers in cell and developmental biology · 2021Review
- TNFR2: Role in Cancer Immunology and Immunotherapy.ImmunoTargets and therapy · 2021Review
- Tumor invasion in draining lymph nodes is associated with Treg accumulation in breast cancer patients.Nature communications · 2020Article
- A review of the research progress in T-lymphocyte immunity and cervical cancer.Translational cancer research · 2020Review
- Article
- Screening the Cancer Genome Atlas Database for Genes of Prognostic Value in Acute Myeloid Leukemia.Frontiers in oncology · 2019Article
- Prognostic Value of the Neo-Immunoscore in Renal Cell Carcinoma.Frontiers in oncology · 2019Article
- TNF Receptor 2 Makes Tumor Necrosis Factor a Friend of Tumors.Frontiers in immunology · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Regulatory T (Treg) cells expressing tumor necrosis factor receptor 2 (TNFR2) are highly suppressive and are associated with immune homeostasis in various diseases. However, the role of TNFR2
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.